NephroGenex (NRX) Stock Skyrockets to One-Year High Today After Lead Drug Safety Announcement

NEW YORK (TheStreet) -- Shares of drug developer NephroGenex  (NRX) skyrocketed more than 285% to a 52-week high of $17.98 on Wednesday after the company announced it found its lead drug to be safe in a cardiac safety study.

The company is evaluating the drug pyridorin in a late-stage trial in patients with diabetic nephropathy, a chronic and degenerative kidney disease caused by diabetes and often tied to heart disease.

NephroGenex said it has noted cardiac safety concerns with other therapies currently in development.

Exclusive Report: Jim Cramer’s Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pyridorin attempts to work on the underlying cause of diabetic nephropathy, which affects approximately 6 million Americans, in order to slow its progression.

More than 12.8 million shares had changed hands as of 11:26 a.m., which dwarfed the daily average volume of 12,733.

NRX Chart NRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk